Holen Sie sich die Stockscreener-App
26.32
0.53%
0.0482
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Trading Systems Reacting to (ARQT) Volatility - Stock Traders Daily
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts - Yahoo! Finance Canada
Arcutis Biotherapeutics (ARQT) Stock Analysis: A 42.53% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential - ChartMill
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 1000 - marketscreener.com
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 600 Health Care - marketscreener.com
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P Composite 1500 - marketscreener.com
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 600 - marketscreener.com
Arcutis Biotherapeutics Inc. (ARQT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Arcutis Biotherapeutics (ARQT) Insider Masaru Matsuda Sells 3,67 - GuruFocus
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares - Investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda Sells 3,674 Shares Under 10b5-1 Plan - kalkinemedia.com
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares By Investing.com - Investing.com UK
Arcutis Biotherapeutics director Welgus sells $114k in shares By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last? - Yahoo Finance
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% - TIKR.com
Former Arcutis (NASDAQ: ARQT) officer plans multimillion-dollar stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) director plans $114K stock sale - Stock Titan
The Technical Signals Behind (ARQT) That Institutions Follow - Stock Traders Daily
Arcutis EVP, Chief Legal Officer Masaru Matsuda sells 9,989 shares for $249,861 - Bitget
Arcutis Biotherapeutics (ARQT) Insider Masaru Matsuda Sells 9,98 - GuruFocus
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock By Investing.com - Investing.com India
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - Investing.com
Arcutis (ARQT) officer lines up Rule 144 stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals - ChartMill
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
(ARQT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
ARQT Stock Price, Quote & News - Syfe
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Nigeria
Arcutis director Terrie Curran sells $956k in shares - Investing.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - theglobeandmail.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K - benzinga.com
Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026 - Kalkine Media
Arcutis Biotherapeutics CMO Patrick Burnett Sells Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Roflumilast Cream 0.3% Approved for Plaque Psoriasis in Children as Young as 2 - Pharmacy Times
Polar Capital Holdings Plc Buys Arcutis Biotherapeutics Inc (ARQ - GuruFocus
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares - Stock Titan
ARQT Looks 18.5% Undervalued on GF Value™ After Health Canada Ap - GuruFocus
PrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis - PR Newswire Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares - MarketBeat
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup - ChartMill
Arcutis (ARQT) Q2 2026 Earnings: EPS Beats Its Estimate in Latest Trading; Shares After the Report: The Stock Ends Up 3.63% at the CloseSegment Revenue Breakdown - Vinanet
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale - Stock Titan
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action? - webull.com
Arcutis (ARQT) Q2 2026 Earnings Call Transcript - AOL.com
Arcutis Biotherapeutics (ARQT) Gains 1.39% as Shares Push Toward Key ResistanceSupport Level Bounce - Vinanet
Liquidity Mapping Around (ARQT) Price Events - Stock Traders Daily
Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals - ChartMill
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
0.39%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):